Novartis Will Pay $390M To Settle False Claims Suit About Marketing Of 4 Drugs

(October 27, 2015, 12:34 PM EDT) -- NEW YORK — One week before trial, Novartis Pharmaceuticals Co. on Oct. 27 announced it has reached an agreement in principle to settle a False Claims Act lawsuit with the United States and various states for $390 million (United States of America, ex rel. David Kester v. Novartis Pharmaceuticals Co., No. 11-8196, S.D. N.Y.).

“Under the agreement, Novartis would pay $390 million to resolve all claims related to Myfortic, Exjade, Tasigna, Gleevec and TOBI,” Novartis said in a press statement. “Finalization of the settlement is contingent...
To view the full article, register now.